Evidence map›Paper›PMID 35562920›Full record

ReviewInternational journal of molecular sciences2022

TRPA1 Role in Inflammatory Disorders: What Is Known So Far?

Lorenzo Landini, Daniel Souza Monteiro de Araujo, Mustafa Titiz, Pierangelo Geppetti, Romina Nassini, Francesco De Logu

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. TRPA1-Related Diseases and Applications of Nanotherapy.International journal of molecular sciences · 2024
    Review
  19. TRPA1, TRPV1, and Caffeine: Pain and Analgesia.International journal of molecular sciences · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lorenzo LandiniDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, 50139 Florence, Italy.ORCID 0000-0002-3933-2497
Daniel Souza Monteiro de AraujoDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, 50139 Florence, Italy.ORCID 0000-0003-1115-725X
Mustafa TitizDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, 50139 Florence, Italy.ORCID 0000-0003-1278-6744
Pierangelo GeppettiDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, 50139 Florence, Italy.
Romina NassiniDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, 50139 Florence, Italy.ORCID 0000-0002-9223-8395
Francesco De LoguDepartment of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, 50139 Florence, Italy.ORCID 0000-0001-8360-6929
University of Florence · IT

Funding

European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme 835286
6 · The paper itself

Abstract

The transient receptor potential ankyrin 1 (TRPA1), a member of the TRP superfamily of channels, is primarily localized in a subpopulation of primary sensory neurons of the trigeminal, vagal, and dorsal root ganglia, where its activation mediates neurogenic inflammatory responses. TRPA1 expression in resident tissue cells, inflammatory, and immune cells, through the indirect modulation of a large series of intracellular pathways, orchestrates a range of cellular processes, such as cytokine production, cell differentiation, and cytotoxicity. Therefore, the TRPA1 pathway has been proposed as a protective mechanism to detect and respond to harmful agents in various pathological conditions, including several inflammatory diseases. Specific attention has been paid to TRPA1 contribution to the transition of inflammation and immune responses from an early defensive response to a chronic pathological condition. In this view, TRPA1 antagonists may be regarded as beneficial tools for the treatment of inflammatory conditions.

Indexed as

Transient Receptor Potential ChannelsCalcium ChannelsCytoskeletal ProteinsGanglia, SpinalTRPA1 Cation ChannelTRPV Cation ChannelsCalcium ChannelsCytoskeletal ProteinsTransient Receptor Potential ChannelsTRPA1 Cation ChannelTRPV Cation Channelsimmune cellsinflammatory cellsinflammatory diseasesTRPA1

Identifiers

PMID35562920
PMCPMC9101260
OpenAlexW4224223616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.